

---

## Greg A. Johnson

---

A Senior Executive with over 25 years of progressive experience in Biotech and Clinical Research, with recognized expertise in strategic planning, project management and operations management, as well as in electronic data capture and the implementation and use of computerized systems in a clinical research setting.

An effective leader, communicator, and decision-maker with significant international experience.

 [greg@cagleyjohnson.com](mailto:greg@cagleyjohnson.com)

 [www.twitter.com/cagleyjohnson](https://www.twitter.com/cagleyjohnson)

 [www.cagleyjohnson.com](https://www.linkedin.com/in/gregjohnson)

 [www.facebook.com/cagleyjohnson](https://www.facebook.com/cagleyjohnson)

---

### Cagley Johnson Consulting Inc. 2011 – Present Canada

---

#### Principal Consultant

**Jun 2011 – Present  
Victoria BC, Canada**

Support pharma, biotech, and CRO clients with:

- Program Management
- Vendor Management
- Portfolio Review
- Project Rescue Support
- Due Diligence for M&A Activities
- System Implementation
- Project Management Maturity Review

Cagley Johnson Consulting Inc. is currently delivering consulting services to:

Kintara Therapeutics ([www.kintara.com](http://www.kintara.com))

- Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC.
- VAL-083 is a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara’s internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
- Kintara is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late stage pivotal testing.
- CJC provides consulting services with Greg functioning as (Acting) Head of Operations for the company.

Rediscovery Life Sciences AKI LLC ([www.rediscoveryls.com](http://www.rediscoveryls.com))

- Rediscovery Life Sciences (RLS) develops new medicines faster, cheaper and with less risk through drug repurposing.
- RLS is developing RLS-003 for Acute Kidney Injury (AKI). RLS-003 has been used in humans for decades for a completely unrelated indication, and has never been approved in the U.S. for any indication.
- CJC provides program management for the RLS-003 drug development program in AKI.

MedGenesis Therapeutix Inc. ([www.medgenesis.com](http://www.medgenesis.com))

- MedGenesis' lead program, glial cell-line derived neurotrophic factor (GDNF), is a potentially disease-modifying treatment for Parkinson's disease that has recently completed Phase 2 clinical studies.
- CJC provides program management support, and website support.
- Greg also serves on the MedGenesis Board of Directors.

Vancouver Hospice Society ([www.vancouverhospice.org](http://www.vancouverhospice.org))

- CJC offers support and maintenance for the Vancouver Hospice Society website on a *pro bono* basis.

---

**MedGenesis Therapeutix Inc.**  
**2007 – 2017**  
**Canada**

---

**Member Board of Directors**

**Apr 2019 – Present**  
**Victoria BC, Canada**

**President and Chief Financial Officer**

**Oct 2012 – Mar 2017**  
**Victoria BC, Canada**

Responsibilities:

- Serve as chair of the Executive Committee, participating in setting corporate strategy
- Develop operational plan, in conjunction with COO, and submit for board approval on an annual basis
- Manage the financial operations of the company
  - Direction and oversight for Accounting and Financial Management activities performed by Controller; including budgeting, short and long-term financial forecasting, management reporting, audit, tax, investment strategies, cash flow management, accounting and related activities
  - Operational accountability for risk management and information systems
  - Responsible for liaising with shareholders, external advisors, and management
  - Responsible with CEO for raising capital as needed
- Manage interactions with Board, Audit Committee, and Compensation Committee
- Contract negotiation and contract management with licensors and licensees, vendors, professional advisors and consultants

Key Accomplishments:

- Negotiated Option and License Agreement for MedGenesis' lead molecule with Pfizer.
- Served as Alliance Manager for MedGenesis/Pfizer Joint Steering Committee.

**Chief Operating Officer  
Senior Vice President, Operations****Mar 2007 - Sep 2012  
Victoria BC, Canada**Responsibilities:

- Serve as member of Executive Committee, participating in setting corporate strategy;
- Develop operational plan, in conjunction with CFO, and submit for board approval on annual basis;
- Provide program leadership and project management for product development including non-clinical, technical operations, clinical operations, quality assurance, and alliance management;
- Report on status of programs in quarterly Board meetings and institute metrics to assess performance against plan;
- Manage relationships with in-licensing partners (UCSF, NIH and Amgen) including ensuring contractual obligations are met and negotiating any contract amendments, and monitor milestones and identify opportunities for enhancing these relationships;
- Lead selection of and negotiations with CROs contracted for clinical trial management, and provide oversight for management of CRO performance against expectations and negotiate all changes in scope;

Key Accomplishments:

- Negotiated three-way License Agreement with Amgen and Biovail to acquire MedGenesis' lead molecule.
- Negotiated termination of agreement with Biovail after their acquisition by Valeant.
- Negotiated collaboration agreement with North Bristol Trust for investigator initiated study for lead molecule.

---

**PRA International  
1992 - 2007  
Germany, UK, USA, Canada**

---

**Vice President, Operations, Americas****Jan 2007 – Feb 2007  
Reston VA, USA**Responsibilities:

- P&L responsibility for Trials Management Centers in USA, Canada, and Latin America.
- Served on Corporate Leadership Team.

**Vice President of Global Data Management**

**May 2006 – Dec 2006  
Reston VA, USA  
Jun 2004 – Apr 2006  
Victoria BC, Canada**

Responsibilities:

- P&L responsibility for 300-person worldwide data management operations.
- Served on Corporate Leadership Team.

Key Accomplishments:

- Oversaw successful implementation of new EDC-based data management system and retirement of legacy system.
- Led successful centralization of global data management services to four offices.
- Established a data management center in Pune, India.
- President's Award winner in 2004.

**Vice President of Operations, Canada**

**Jul 2002 – May 2004  
Victoria BC, Canada**

Responsibilities:

- P&L responsibility for Trials Management Centers in Victoria, BC and Ottawa, ON.
- Served on Corporate Leadership Team.

Key Accomplishments:

- Led successful operations integration of CroMedica acquisition.
- President's Award winner in 2002.

**Director of Product Management  
Product Director, Data Management  
Senior Systems Program Manager**

**Feb 1998 – Jun 2002  
Charlottesville VA, USA**

Responsibilities:

- Responsible for developing product methodologies, process documents, reports, and other standard infrastructure for functional operating groups.
- Responsible for implementing, maintaining, upgrading and retiring computerized systems for functional operating groups.

- Involved in due diligence and integration activities for multiple acquisitions.
- Served on Corporate Leadership Team.

Key Accomplishments:

- Successfully implemented global data management system and retired multiple legacy data management systems.
- Oversaw Y2K mitigation efforts for data management systems.
- Oversaw successful implementation of global system for document imaging.
- Led Product Management group in laying groundwork for company to eventually establish ISO 9000 Quality Management certification.
- Participated in due diligence and integration activities for multiple international acquisitions.
- President's Award winner in 2001.

**Manager, International Data Centre**

**Dec 1996 – Jan 1998  
Swansea, South Wales, UK**

Responsibilities:

- Responsible for establishment and management of European Data Management Centre.

Key Accomplishments:

- Established a data management centre in Wales and achieved profitability in first year of operation.

**Supervisor Information Technology  
Supervisor Clinical Data Services**

**Apr 1994 – Nov 1996  
Mannheim, Germany**

**Supervisor Information Technology**

**Nov 1992 – Mar 1994  
Mannheim, Germany**

---

## Qualifications

---

- **Master of Science**, Clinical Research (with distinction)  
Jul 2000, Liverpool John Moores University
- Project Management Professional (**PMP**) Certification  
May 2001 - Current  
Certification Number: 33205  
Project Management Institute
- Fellow, Institute of Clinical Research (**FICR**)  
Jun 2006 - Current  
Institute of Clinical Research
- MBTI® Certified Practitioner  
May 2011 – Current

---

## Publications

---

Guo, C, Yang, Q, Li, J, Wu, S, Deng, M, Du, X, Ke Sai, K, Jiang, X, Chen, Z, Zhang, J, Lin, F, Wang, J, Chen, Y, Ke, C, Zhang, X, Ju, X, Mou, Y, Bacha, J, Steino, A, Kanekal, S, Kwan, C, **Johnson, GA**, Schwartz, R, Langlands, J, Brown, D, Chen, Z-p. "Phase 2 clinical trial of VAL 083 as first line treatment in newly-diagnosed MGMT unmethylated glioblastoma multiforme (GBM): Halfway report." *Glioma* 2020; 2:167-73.

Whone, A, Luz, M, Boca, M, Woolley, M, Mooney, L, Dharia, S, Broadfoot, J, Cronin, D, Schroers, C, Barua, NU, Longpre, L, Barclay, CL, Boiko, C, **Johnson, GA**, Fibiger, HC, Harrison, R, Lewis, O, Pritchard, G, Howell, M, Irving, C, Johnson, D, Kinch, S, Marshall, C, Lawrence, AD, Blinder, S, Sossi, V, Stoessl, AJ, Skinner, P, Mohr, E, Gill, SS. "Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease." *Brain* 2019; 142:512–525.

Whone, AL, Boca, M, Luz, M, Woolley, M, Mooney, L, Dharia, S, Broadfoot, J, Cronin, D, Schroers, C, Barua, NU, Longpre, L, Barclay, CL, Boiko, C, **Johnson, GA**, Fibiger, HC, Harrison, R, Lewis, O, Pritchard, G, Howell, M, Irving, C, Johnson, D, Kinch, S, Marshall, C, Lawrence, AD, Blinder, S, Sossi, V, Stoessl, AJ, Skinner, P, Mohr, E, Gill, SS. "Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease." *Journal of Parkinson's Disease* 2019; 1–13.

Grahn, AY, Bankiewicz, KS, Dugich-Djordjevic, M, Bringas, JR, Hadaczek, P, **Johnson, GA**, Eastman, S and Luz, M. "Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience." *J Neurooncol* 2009; 95:185–197.

Walsh, WM, and **Johnson, GA**. "Validation: Never an Endpoint – A Systems Development Life Cycle Approach to Good Clinical Practice." *Drug Information Journal* 2001; 35:809-817.

---

## Posters

---

O'Brien, BJ, Kamiya-Matsuoka, C, Weathers, S-P, Yung, WKA, Loghin, M, Harrison, R, Majd, N, Knight, S, Liu, D, Bacha, JA, Brown, DM, Steino, A, **Johnson, GA**, Kanekal, S, Langlands, J, Lopez, LM, Schwartz, R, Penas-Prado, M, De Groot, J. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the AACR Annual Meeting 2021, Virtual Meeting, April 2021.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Bacha, J, Steino, A, Brown, D. "Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM" presented at the AACR Annual Meeting 2021, Virtual Meeting, April 2021.

Chen, Z-p, Guo, C-c, Yang, Q-y, Li, J-w, Wu, S-x, Bacha, J, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Steino, A, Lopez, LM, Brown, D. "Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM" presented at the Society of Neuro-Oncology Virtual Conference, November 2020.

O'Brien, B, Penas-Prado, M, Kamiya-Matsuoka, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Majd, N, Knight, S, Bacha, J, Brown, D, **Johnson, GA**, Langlands, J, Schwartz, R, Kanekal, S, Steino, A, Lopez, L, DeGroot, J. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT un-methylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting" presented at the Society of Neuro-Oncology Virtual Conference, November 2020.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Bacha, J, Steino, A, Brown, D. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma" presented at the American Association for Cancer Research Annual Meeting 2020, Virtual Annual Meeting II.

O'Brien, BJ, Kamiya-Matsuoka, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Majd, N, Bacha, JA, Brown, DM, Steino, A, **Johnson, GA**, Kanekal, S, Langlands, J, Lopez, LM, Schwartz, R, Penas-Prado, M, De Groot, J. "Phase 2 study of dianhydrogalactitol (VAL083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the American Association for Cancer Research Annual Meeting 2020, Virtual Annual Meeting II.

O'Brien, B, Penas-Prado, M, Kamiya, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Bacha, J, Brown, D, **Johnson, GA**, Langlands, J, Schwartz, R, Kanekal, S, Lopez, L, deGroot, J. "Phase 2 Study of Dianhydrogalactitol (Val-083) In Patients with MGMT-Unmethylated, Bevacizumab-Naïve Glioblastoma in the Recurrent and Adjuvant Setting" presented at the Society of Neuro-Oncology Annual Meeting, Phoenix, November 2019.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, Bacha, J, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Lopez, L, Brown, D. "Clinical Trial of Val-083 in Newly Diagnosed MGMT-Unmethylated GBM: Half-Way Report" presented at the Society of Neuro-Oncology Annual Meeting, Phoenix, November 2019.

O'Brien, BJ, De Groot, J, Kamiya-Matsuoka, C, Weathers, S-P, Bacha, JA, Brown, DM, Steino, A, Langlands, J, **Johnson, GA**, Schwartz, R, Kanekal, S, Lopez, LM, and Penas-Prado, M. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the American Association for Cancer Research Annual Meeting, Atlanta, April 2019.



Chen, Z-p, Guo, C, Bacha, J, Langlands, J, Steino, A, Kwan, C, Kanekal, S, **Johnson, GA**, Schwartz, R, Lopez, LM, Brown, D. "Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma" presented at the American Association for Cancer Research Annual Meeting, Atlanta, April 2019.

The GDNF Study Group. "Glial Cell Line-Derived Neurotrophic Factor (GDNF): Indication of Biologically Mediated Clinical Benefit in Parkinson's Disease After 80 Weeks of Treatment via Intermittent Intraputamenal Convection-Enhanced Delivery (CED)". [abstract]. *Mov Disord.* 2017.

The GDNF Study Group. "Randomized Parkinson's Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery". [abstract]. *Mov Disord.* 2017.

Luz, M, Dugich-Djordjevic, M, Bringas, JR, Hadaczek, P, **Johnson, GA**, Grahn, AY, Eastman, S, and Bankiewicz, KS. "Convection-enhanced Delivery of Nanoliposomal Topotecan and Gadodiamide in Rodent Intracranial Brain Tumor Xenografts and Normal Brain" presented at the Society of Neuro-Oncology Annual Meeting, Las Vegas, November 2008.

---

## Presentations

---

**Johnson, GA.** "Global Clinical Data Management and Electronic Data Capture," presented at Mahratta Chamber of Commerce Industries and Agriculture (MCCIA), Pune, India, 2006.

**Johnson, GA.** "Deployment of a Hybrid Data Management System," presented at the DIA Annual Meeting, Philadelphia, 2006.

Richards, N, and **Johnson, GA.** "Conducting True Hybrid Studies Using EDC and Paper Data Entry Together in the Same Trial," presented at EDC and Beyond: Leveraging Electronic Applications to Improve Data Accessibility for Rapid Decision Making, Las Vegas, 2006.

**Johnson, GA.** "Segways, TiVos, and Electronic Data Capture: new technology is always cool, but does it always add value?" keynote presentation at the Pharmaceutical Technology Congress, Philadelphia, 2005.

**Johnson, GA.** "Novel Processes in Support of CDM," session chair at the Annual Fall Conference of the Society for Clinical Data Management, Arlington VA, 2000.

Walsh, WM, and **Johnson, GA.** "Validation: Never an Endpoint – Implementing a Systems Development Life Cycle," presented at the DIA Workshop for Clinical Data Management, Philadelphia, 2000.

**Johnson, GA,** and Hanson, M. "Complying with New Industry Guidance on Computerized Systems Used in Clinical Trials," presented at the Annual Fall Conference of the Society for Clinical Data Management, Chicago, 1999.

**Johnson, GA,** and Hanson, M. "Conducting Vendor Audits," presented at North American Recorder Users Group, Chicago, 1999.

Newman, ML, and **Johnson, GA.** "Implementing New Technology (The Training Aspects of a New Global Data Management System)," presented at the Annual Fall Conference of the Society for Clinical Data Management, Washington, 1998.

**Johnson, GA.** "Experience with Recorder V3.1," presented at North American Recorder Users Group, Philadelphia, 1998.

Thier, E, (chair), Bridgman, A, Cummings, S, **Johnson, GA**, O'Donoghue, P, Tebbs, P, and Thomas, S. "Build versus Buy - The Challenge of New Software," panel discussion at the DIA Workshop for Clinical Data Management, Paris, 1997.

**Johnson, GA**, and Handelsman, D. "Combining Global Clinical Databases," presented at the DIA Workshop for Clinical Data Management, London, 1996.